436 related articles for article (PubMed ID: 23666528)
1. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.
Hebron ML; Lonskaya I; Moussa CE
Hum Mol Genet; 2013 Aug; 22(16):3315-28. PubMed ID: 23666528
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance.
Hebron ML; Lonskaya I; Moussa CE
Autophagy; 2013 Aug; 9(8):1249-50. PubMed ID: 23787811
[TBL] [Abstract][Full Text] [Related]
3. α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment.
Karim MR; Liao EE; Kim J; Meints J; Martinez HM; Pletnikova O; Troncoso JC; Lee MK
Mol Neurodegener; 2020 Apr; 15(1):27. PubMed ID: 32299471
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
[TBL] [Abstract][Full Text] [Related]
5. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Lee S; Kim S; Park YJ; Yun SP; Kwon SH; Kim D; Kim DY; Shin JS; Cho DJ; Lee GY; Ju HS; Yun HJ; Park JH; Kim WR; Jung EA; Lee S; Ko HS
Hum Mol Genet; 2018 Jul; 27(13):2344-2356. PubMed ID: 29897434
[TBL] [Abstract][Full Text] [Related]
6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Lopez-Cuina M; Guerin PA; Canron MH; Delamarre A; Dehay B; Bezard E; Meissner WG; Fernagut PO
Mov Disord; 2020 Jul; 35(7):1163-1172. PubMed ID: 32291831
[TBL] [Abstract][Full Text] [Related]
9. Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration.
Kim H; Shin JY; Jo A; Kim JH; Park S; Choi JY; Kang HC; Dawson VL; Dawson TM; Shin JH; Lee Y
Brain; 2021 Dec; 144(12):3674-3691. PubMed ID: 34581802
[TBL] [Abstract][Full Text] [Related]
10. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
Mahul-Mellier AL; Fauvet B; Gysbers A; Dikiy I; Oueslati A; Georgeon S; Lamontanara AJ; Bisquertt A; Eliezer D; Masliah E; Halliday G; Hantschel O; Lashuel HA
Hum Mol Genet; 2014 Jun; 23(11):2858-79. PubMed ID: 24412932
[TBL] [Abstract][Full Text] [Related]
11. Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease.
Lonskaya I; Hebron ML; Algarzae NK; Desforges N; Moussa CE
Neuroscience; 2013 Mar; 232():90-105. PubMed ID: 23262240
[TBL] [Abstract][Full Text] [Related]
12. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Karuppagounder SS; Brahmachari S; Lee Y; Dawson VL; Dawson TM; Ko HS
Sci Rep; 2014 May; 4():4874. PubMed ID: 24786396
[TBL] [Abstract][Full Text] [Related]
13. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.
Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC
J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154
[TBL] [Abstract][Full Text] [Related]
14. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease.
Karuppagounder SS; Wang H; Kelly T; Rush R; Nguyen R; Bisen S; Yamashita Y; Sloan N; Dang B; Sigmon A; Lee HW; Marino Lee S; Watkins L; Kim E; Brahmachari S; Kumar M; Werner MH; Dawson TM; Dawson VL
Sci Transl Med; 2023 Jan; 15(679):eabp9352. PubMed ID: 36652533
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.
Werner MH; Olanow CW
Mov Disord; 2022 Jan; 37(1):6-15. PubMed ID: 34816484
[TBL] [Abstract][Full Text] [Related]
16. Treadmill exercise intervention improves gait and postural control in alpha-synuclein mouse models without inducing cerebral autophagy.
Minakaki G; Canneva F; Chevessier F; Bode F; Menges S; Timotius IK; Kalinichenko LS; Meixner H; Müller CP; Eskofier BM; Casadei N; Riess O; Schröder R; Winkler J; Xiang W; von Hörsten S; Klucken J
Behav Brain Res; 2019 May; 363():199-215. PubMed ID: 30599154
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Pagan FL; Hebron ML; Wilmarth B; Torres-Yaghi Y; Lawler A; Mundel EE; Yusuf N; Starr NJ; Arellano J; Howard HH; Peyton M; Matar S; Liu X; Fowler AJ; Schwartz SL; Ahn J; Moussa C
Pharmacol Res Perspect; 2019 Apr; 7(2):e00470. PubMed ID: 30906562
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
Imam SZ; Trickler W; Kimura S; Binienda ZK; Paule MG; Slikker W; Li S; Clark RA; Ali SF
PLoS One; 2013; 8(5):e65129. PubMed ID: 23741470
[TBL] [Abstract][Full Text] [Related]
20. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
